Abzu reveals insights in Peptomyc’s first-ever clinically viable Myc oncogene inhibitor

The QLattice® discovery engine developed by Abzu® has accelerated scientific exploration and understanding again, this time for Peptomyc®, a biotech focused on inhibiting the cancer-causing protein Myc.

Built on over 20 years’ research led by Laura Soucek, co-Director of the Vall d’Hebron Institute of Oncology’s (VHIO) Preclinical and Translational Research Program and co-founder and Chief Executive Director of Peptomyc, Omomyc (OMO-103) is a therapeutic mini-protein which targets and inhibits the Myc oncogene.

The Myc oncogene is persistently expressed in Burkitt lymphoma as well as many cervix, colon, breast, lung, pancreatic, and stomach cancers, making it one of the most sought-after drug targets in cancer. Until Peptomyc’s successful clinical trial with OMO-103, Myc was thought to be undruggable.

Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.

“Partnering with Abzu and using the QLattice increased our ability to really take advantage of all our clinical results to find unexpected and extremely valuable data that we could have missed otherwise,” says Laura Soucek, co-founder and Chief Executive Director of Peptomyc.

“By helping scientists in understanding treatment response earlier, we’re enabling them to bring drugs to market faster,” says Marco Salvatore, Head of Target and Biomarker Discovery at Abzu. “This is an extraordinary achievement for Peptomyc, and we’re thrilled to have contributed to this scientific progress.”

OMO-103 is ready to move to a phase II study early 2023.

About Abzu

Abzu® was born from the desire to challenge the fundamental assumptions of contemporary, black-box AI. Abzu’s pioneering technology, the QLattice®, is a research engine that accelerates exploration, enabling scientists to bring drugs to market faster.

The QLattice introduces a new standard of interpretability and explainability to life science data sets. Through simple models and straightforward mathematical expressions, Abzu’s QLattice achieves a level of transparency and performance in machine learning that is disrupting domains previously dominated by opaque and cumbersome models.

Founded in January 2018, Abzu is a deep tech startup with offices in Copenhagen, Denmark and Barcelona, Spain. Abzu derives its name from Ancient Sumerian, meaning “the source of the waters of wisdom”.

Abzu has raised a total of €8,1M, and last closed a seed round in April 2021 for €4.9M.

About Peptomyc

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

To learn more, visit www.peptomyc.com.

Share this press release

More press releases

Get notified

Subscribe to receive a notification when there’s news about Abzu. You can opt out at any time.

We’re cookieless, and our privacy policy is actually easy to read.

Contact Abzu

It’s easy to get in touch with an Abzoid.

Contact form

Fill out the form below, and an Abzoid will be in touch in 24 hours.

Email us

Email Marketing at elyse.sims@abzu.ai or info@abzu.ai.

Call us

Reach us during standard CET business hours at +45 31 23 47 64.